+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hemoglobinopathies Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • PDF Icon

    Report

  • 120 Pages
  • January 2022
  • Region: Global
  • Mordor Intelligence
  • ID: 5529347

The global hemoglobinopathies treatment market was studied and projected to grow with a CAGR of nearly 7% over the forecast period. The growth is primarily due to an increase in the cases of hemoglobinopathies, coupled with growing awareness pertaining to hemoglobin disorders. According to the World Health Organization, about 1.1% of the couples globally are at the risk of having a child with hemoglobin disorder and prevalence was estimated at 2.55 per 1000. In addition, the presence of strong product pipeline for the treatment of hemoglobinopathies and continuous efforts from the market players and government in developing the new therapies for the same are anticipated to boost the market growth. However, low awareness related to the hemoglobinopathies in low and some of the middle-income countries is anticipated to hamper the market growth. Moreover, the initiatives such as newborn screening for detection of potential disorders are lead by the government and private organizations are anticipated to fuel the market growth for hemoglobinopathies treatment.



Key Market Trends


Sickle Cell Anemia Anticipated to Grow at Significant Rate


  • Sickle cell anemia refers to the group of blood disorders that cause misshape of red blood cells. This makes difficult for RBC to carry oxygen to different organs and tissues. Poor oxygen in the blood may lead to severe pain syndromes, necrosis and bacterial infections.
  • The growing number of cases with sickle cell anaemia globally, coupled with the presence of a robust pipeline of drugs for the treatment of disease is anticipated to boost the segment growth over the forecast period.
  • Drugs used for symptoms of hemoglobinopathies treatment include antibiotics, analgesics, ACE inhibitors. Further, Blood transfusion or stem cell therapy is one of the preferred treatments for hemoglobinopathies. Moreover, increasing research on the treatment of hemoglobinopathies such as gene therapies advancing the market growth.
  • The World Health Organization has estimated that each year about 300000 babies are born with a severe form of inherited blood disorders, and 5% of the world population carries trait genes for haemoglobin disorders, mainly, sickle cell anaemia and thalassemia. Thus the growing incidence of hemoglobinopathies coupled with the rise in R&D investment for the development of treatment options expected to boost the market over the forecast period.

Europe is Anticipated to Have Significant Growth


Among the regional segments, Europe is anticipated to have significant market growth over the forecast period. The growth is attributed to a high number of hemoglobinopathies cases especially in Mediterranean countries, new product launches and growing awareness regarding the disorder. North America is anticipated to have notable market growth owing to well-established healthcare infrastructure for early diagnosis and treatment of hemoglobinopathies and initiatives by the government and non-government organizations to increase the awareness.



Competitive Landscape


Global hemoglobinopathies treatment market is moderately fragmented and competitive. Market players are focusing on new product launches, product innovations and geographical expansion. For instance, in May 2017, Sangamo Therapeutics and Pfizer announced a collaboration for the haemophilia A gene therapy. The key market players operating in the market include Sanofi S.A., Global Blood Therapeutics, Inc., bluebird bio, Inc. EMI Holding, Inc. and Celgene Corporation among others.



Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support


This product will be delivered within 2 business days.

Table of Contents

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Genetic Blood Disorders
4.2.2 Presence of Robust Pipeline
4.3 Market Restraints
4.3.1 Low Awareness Regarding Hemoglobinopathies
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Treatment
5.1.1 Stem Cell Therapy
5.1.2 Blood Transfusion
5.1.3 Iron Chelation Therapy
5.1.4 Others
5.2 By Application
5.2.1 Thalassemia
5.2.2 Sickle Cell Anaemia
5.2.3 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Sanofi S.A.
6.1.2 Global Blood Therapeutics, Inc.
6.1.3 bluebird bio, Inc.
6.1.4 EMI Holding, Inc.
6.1.5 Celgene Corporation
6.1.6 Gamida Cell
6.1.7 Prolong Pharmaceuticals, LLC.
6.1.8 Sangamo Therapeutics Inc.
6.1.9 Silence Therapeutics
7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Methodology

Loading
LOADING...